Andrius Žučenka: The results of our novel 4-drug regimen G-ACTIVE for FLT3 mutated relapsed/refractory acute myeloid leukemia
Andrius Žučenka, Hematologist, Researcher, Lecturer and PhD Candidate at Vilnius University Hospital Santaros Klinikos, made the following post on LinkedIn:
“Our recent paper on combined targeted therapy for FLT3 mutated relapsed/refractory acute myeloid leukemia has just been published!
In this report we demonstrate the results of our novel 4-drug regimen G-ACTIVE, consisting of the FLT3 inhibitor Gilteritinib, BCL-2 inhibitor Venetoclax, and two low-dose chemotherapy agents (Cytarabine and Actinomycin D). Our treatment resulted in a 95% overall response rate, a median overall survival of 32 months and allowed the majority of patients to proceed to curative allogeneic stem cell transplantation.
For more details/manuscript please contact me.”
Read further.
Source: Andrius Žučenka/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023